Impact of Zip-Based Social Determinants on Textbook Outcomes and Survival of Resected Early-Stage NSCLC [0.03%]
基于压缩地段的社会决定因素对早期间期NSCLC患者手术预后及生存的影响研究
Ahmed Alnajar,Benjamin Nguyen,Nestor Villamizar et al.
Ahmed Alnajar et al.
Background: This study investigates the impact of ZIP-code-based social determinants of health (SDH) on textbook oncological outcomes (TOO) and overall survival (OS) in patients with surgically resected clinical stage IA/...
Semiconductor FDG PET/CT for Preoperative Identification of Grade 3 Invasive Nonmucinous Adenocarcinoma [0.03%]
术前识别3级非粘液腺癌侵袭的半导体FDG PET/CT
Hirotsugu Notsuda,Yuyo Suzuki,Ken Onodera et al.
Hirotsugu Notsuda et al.
Purpose: To evaluate the diagnostic performance of semiconductor 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (sPET/CT) for identifying grade 3 invasive nonmucinous adenocarcinoma (INMA) a...
Streamlining the Frequency, Conduct, and Location of Assessments in Registrational Lung Cancer Clinical Trials for Supplemental Applications: Recommendations of a LUNGevity Foundation Multistakeholder Working Group [0.03%]
LUNGevity基金会多方工作组关于补充申请的注册肺癌临床试验的评估频率、流程和地点的建议：简化评估次数、流程和位置
Joseph Tod Guidry,David P Carbone,Melissa L Johnson et al.
Joseph Tod Guidry et al.
The amount of data collected in oncology clinical trials has grown exponentially over recent years, posing significant burdens on trial participants, investigators, and trial sites. The frequency, magnitude, and strict standardization of tr...
An Observational Population Level Study of Neoadjuvant Chemoimmunotherapy for Resectable Non-Small-Cell Lung Cancer [0.03%]
可切除非小细胞肺癌新辅助化疗免疫治疗的流行病学研究
Siddhartha Goutam,Amanda J W Gibson,Michelle Liane Dean et al.
Siddhartha Goutam et al.
Background: Neoadjuvant chemoimmunotherapy (NCIT) is being increasingly used in the treatment of resectable and early-stage NSCLC based on recent randomized controlled trials. The real-world effectiveness of this approach...
Poor Performance Status Associated With Inferior Tarlatamab Outcomes in a Large, Multi-institution Real-World Database of Patients With 2L + ES-SCLC [0.03%]
基于多机构真实世界数据库评估的三线及以上的广泛期小细胞肺癌患者中，较差的状态评分与Tarlatamab疗效不佳相关
Adam A Barsouk,Maxim Yaskolko,Jonathan H Sussman et al.
Adam A Barsouk et al.
Purpose: Tarlatamab is approved for 2L + extensive-stage small cell lung cancer. In previously published retrospective studies, tarlatamab resulted in inferior survival compared to that observed in the DeLLphi-304 trial. ...
Outcomes Based on Age in CALGB 140503 (Alliance): Lobar Versus Sublobar Resection for Peripheral Stage IA Non-small Cell Lung Cancer [0.03%]
CALGB 140503（联盟）基于年龄的结果：对于周围期IA期非小细胞肺癌的叶段切除与亚肺叶切除效果的研究
Apar Kishor Ganti,Bryce Damman,Xiaofei Wang et al.
Apar Kishor Ganti et al.
Objective: In CALGB trial 140503, sublobar resection was not inferior to lobar resection for T1aN0 (size ≤ 2 cm) non-small cell lung cancer (NSCLC) patients. This analysis compares the effect of age on outcomes with the ...
Next-Generation Sequencing Completion and Timeliness Using a Reflex Testing Protocol for Patients with Stage II to IV Nonsquamous Non-Small Cell Lung Cancer [0.03%]
二期至四期非小细胞肺癌患者的下一代测序的完成情况和及时性采用反射检测协议
Gordon Smilnak,Rishika Singh,Sean C Dougherty et al.
Gordon Smilnak et al.
Background: Next-generation Sequencing (NGS) is critical for providing treatment recommendations across multiple stages of non-small cell lung cancer (NSCLC). However, a substantial proportion of patients do not undergo t...
Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant Non-Small Cell Lung Cancer: Final Analysis of the Phase 2, Single-Arm DESTINY-Lung05 Trial [0.03%]
关于DESTINY-Lung05研究：德曲妥珠单抗治疗经治HER2突变型非小细胞肺癌中国患者的最终分析结果
Ying Liu,Dairong Li,Lin Wu et al.
Ying Liu et al.
Introduction: Trastuzumab deruxtecan (T-DXd) was approved in China in October 2024 for previously treated human epidermal growth factor receptor 2 (HER2)-mutant (HER2m) unresectable/metastatic non-small cell lung cancer (...
Quitting Smoking and Two-Year Survival After a Diagnosis of Small-Cell Lung Cancer [0.03%]
吸烟与小细胞肺癌诊断后的两年生存率之间的关系
Rachel E Gemine,Gareth R Davies,Keir E Lewis;LungCAST Investigators
Rachel E Gemine
Background: Smoking at diagnosis is associated with worse survival in non-small-cell lung cancer, and quitting is independently associated with better 2-year survival. The effects of smoking status at baseline and smoking...
Accelerating Lung Cancer Management Through Previsit Liquid Biopsy: Results From the LUNG-FAST Pilot Study [0.03%]
基于LUNG-FAST计划研究的就诊前液体活检加速肺癌管理的功效评估
Eric K Singhi,Natalie Sanchez,Natalie Vokes et al.
Eric K Singhi et al.
Background: Timely molecular profiling is essential for treatment selection in non-small cell lung cancer (NSCLC), yet delays in biomarker testing remain common. We evaluated the feasibility and early clinical impact of a...